Literature DB >> 21140686

Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

Lian-Yuan Tao1, Lei Cai, Xiao-Dong He, Wei Liu, Qiang Qu.   

Abstract

Serum tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen, carbohydrate antigen (CA) 19-9, CA242, and CA50 were analyzed to evaluate their diagnostic values in single and combined tests for distinguishing intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC). Preoperative serum levels of AFP, carcinoembryonic antigen, CA19-9, CA242, and CA50 were measured in 45 ICC and 76 HCC patients. The serum levels and the positive rate of AFP, CA19-9, and CA242 were significantly different between the ICC patients and HCC patients. Although AFP (-) was the most sensitive assay for distinguishing ICC from HCC (91.1%), its specificity was significantly lower than that of CA242 (+) and CA19-9 (+). The combination of AFP (-) and CA242 (+) afforded a high specificity of 94.3 per cent and showed highest accuracy (78.5%). Evaluation of patients without liver cirrhosis also showed similar results. The diagnostic value of CA242 (+) is better than that of CA19-9 (+) and AFP (-) in distinguishing ICC from HCC. Combined detection of AFP (-) and CA242 (+) can improve the specificity and accuracy of diagnosing ICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140686

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  24 in total

1.  Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma.

Authors:  Jinyan Zhang; Tao Huang; Fan Zhang; Junming Xu; Guoqing Chen; Xiaoliang Wang; Li Huang; Zhihai Peng
Journal:  Tumour Biol       Date:  2015-03-19

2.  Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.

Authors:  Liang-He Lu; Yong-Fa Zhang; Wei Wei; Ming Shi; Rong-Ping Guo
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

Review 3.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

4.  Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.

Authors:  Kevin C Corbit; Camella G Wilson; Dylan Lowe; Jennifer L Tran; Nicholas B Vera; Michelle Clasquin; Aras N Mattis; Ethan J Weiss
Journal:  JCI Insight       Date:  2019-08-08

5.  Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.

Authors:  Takayoshi Nishioka; Shoji Kubo; Shogo Tanaka; Kenichi Wakasa; Shigekazu Takemura; Masahiko Kinoshita; Genya Hamano; Yuko Kuwae; Toshihiko Shibata; Shigefumi Suehiro
Journal:  Liver Cancer       Date:  2016-03-17       Impact factor: 11.740

6.  Prediction of Multiple Serum Tumor Markers in Hepatolithiasis Complicated with Intrahepatic Cholangiocarcinoma.

Authors:  Hua Zhao; Benliang Lu
Journal:  Cancer Manag Res       Date:  2022-01-19       Impact factor: 3.989

Review 7.  Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.

Authors:  Yun-Feng Wang; Fei-Ling Feng; Xu-Hong Zhao; Zhen-Xiong Ye; He-Ping Zeng; Zhen Li; Xiao-Qing Jiang; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

8.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

9.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

10.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.